MIMETAS has introduced OrganoPlate UniFlow (UF), the first commercial platform offering unidirectional, gravity-driven pumpless flow systems for disease research. This innovation significantly advances tissue model development for pharmaceutical research by replicating physiological conditions without complex equipment.

Technical foundations of the platform

The OrganoPlate UF technology addresses fundamental limitations in traditional microphysiological systems by establishing stable unidirectional flow conditions that more accurately mirror in vivo circulation. This gravity-driven mechanism eliminates the need for external pumps whilst maintaining consistent flow parameters critical for vascular, immunological and oncological models.

The platform’s technical architecture supports up to 512 individual microfluidic chips within a single experimental setup, enabling high-throughput screening whilst preserving biological relevance. This scalability makes the system particularly valuable for large-scale drug discovery programmes requiring robust statistical validation.

Applications in disease-specific modelling

OrganoPlate UF has been successfullyintegrated into MIMETAS’ existing portfolio of tissue models including liver, lung, brain, vasculature and tumour systems. The technology shows particular promise for studies involving endothelial function, immune cell trafficking and metabolic disease mechanisms.

“The MIMETAS OrganoPlate has led the field in microphysiological cell culture for over 12 years,” said Bas Trietsch, MIMETAS co-founder. “With UniFlow, we’ve achieved unidirectional flow that mimics blood circulation while maintaining the ease of use, compatibility, and throughput that make our technology exceptional.”

Implementation considerations

The system’s design priorities include integration with standard laboratory equipment, compatibility with automated liquid handling systems and microscopy platforms. This ensures straightforward implementation within existing research infrastructures without requiring specialist technical expertise.

Long-term culture stability represents another significant advancement, allowing researchers to maintain complex tissue models for extended periods – a critical requirement for chronic disease studies and longitudinal therapeutic investigations. MIMETAS, founded in 2013 and headquartered in Leiden, Netherlands, operates globally across Europe, Asia and the USA. The company specialises in human-relevant disease models for pharmaceutical discovery and development, with the OrganoPlate technology serving as its foundational platform.

OrganoPlate UF technology is now available as part of MIMETAS’ service portfolio, offering pharmaceutical researchers access to enhanced microfluidic systems for preclinical drug development and disease mechanism investigation.

For more information, visit: https://www.mimetas.com
Digital issue: Please click here for more information